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Abstract
The F508del mutation impairs trafficking of the cystic fibrosis transmembrane conductance regulator (CFTR) to the plasma membrane and results in a partially functional chloride channel that is retained in the endoplasmic reticulum and degraded. We recently used a novel High Throughput Screening (HTS) assay to identify small molecule correctors of F508del CFTR trafficking and found several classes of hits in a screen of 2000 compounds (Carlile et al., 2007) . In the present study we have extended the screen to 42,000 compounds and confirmed sildenafil as a corrector using this assay. We evaluated structural analogues of sildenafil and found that one such molecule called KM11060 (7-chloro-4-{4-[(4-chlorophenyl) sulfonyl] piperazino}quinoline) was surprisingly potent. It partially restored 
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Introduction
Cystic Fibrosis (CF) is a common lethal genetic disease affecting Caucasians and is caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) Riordan et al., 1989) . CFTR is a cAMP-regulated anion channel expressed in airway, intestinal, pancreatic, and other epithelia that regulate luminal fluid volume and composition in the respiratory and gastrointestinal tracts. Airway mucus becomes viscous in people with CF, which disrupts normal mucociliary clearance of inhaled pathogens and leads to recurring airway infection. Intestinal epithelia are also abnormal and intestinal obstruction (meconium ileus) is common in CF newborns.
Over 1546 mutations have been documented in the CFTR gene (www.genet.sickkids.on.ca) but the most common by far is a phenylalanine deletion (F508del) in the first nucleotide binding domain, which is present on at least one chormosome in ~90% of people with CF (Bobadilla, 2002) . This mutation impairs folding, trafficking, membrane stability, and channel gating (Cheng et al., 1990; Denning et al., 1992; Lukacs et al., 1993) , leading to reduced CFTR expression and chloride conductance in the apical membrane and other abnormalities. Misfolded F508del-CFTR protein is retained in the endoplasmic reticulum (ER) but can be rescued by low temperature (<30°C) and by chemical chaperones such as phenylbutyrate or glycerol (Denning et al., 1992; Brown et al., 1996; Rubenstein et al., 1997) , although the mutant has a shorter half-life in the plasma membrane (Lukacs et al., 1993) and is less responsive to cAMP stimulation (Hwang et al., 1997) . Rescue of only 10-15% of the ER-retained F508del-CFTR may be sufficient to provide therapeutic benefit (Farmen et al., 2005) , therefore identifying pharmacological agents which can partially correct the trafficking defect associated with this mutation could benefit most CF patients.
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High throughput screening (HTS) has recently been used to identify small molecules that increase F508del-CFTR activity (Galietta et al., 2001; Van Goor et al., 2006; Carlile et al., 2007) . Such molecules have been categorized according to whether they alleviate the folding/cellular processing defect (correctors), or increase the responsiveness of F508del-CFTR channels already present in the membrane to cAMP activation (potentiators). Two well characterized families of F508del-CFTR potentiators are the xanthines, notably 1,3-diallyl-8-cyclohexylxanthine and 3,7-dimethyl-1-isobutyl xanthine, and the flavones, such as genistein, apigenin and kaempferol (Drumm et al., 1991; Hwang et al., 1997; Lim et al., 2004) . Other potentiators include tetrahydrobenzothiophene, phenylglycine, sulfonamide and derivatives of pyrrolo [2,3-b] pyrazines (Al-Nakkash and Hwang and Sheppard, 1999; Yang et al., 2003; . Fewer correctors have been reported, and some of these (eg 4-phenylbutyrate and curcumin) partially correct the processing defect in vitro but are less efficacious when used in vivo (Rubenstein et al., 1997; Rubenstein and Zeitlin, 1998; Egan et al., 2004; Mall and Kunzelmann, 2005) . Other families with corrector activity include the aminoarylthiazoles, bisaminomethylbithiazoles, the quinazoline corrector VRT-325, benzo[c]quinoliziniums such as MPB-07, and the alpha-glucosidase inhibitor miglustat (Dormer et al., 2001; Loo et al., 2005; Norez et al., 2006; Van Goor et al., 2006) . Sildenafil has also been shown to correct F508del-CFTR processing when used at high micromolar concentrations (Dormer et al., 2005; Poschet et al., 2007) . Here we report the identification and characterization of a novel F508del-CFTR corrector that is related to sildenafil, but which rescues trafficking with much higher potency in several model systems including unpolarized cells, human airway epithelial cell monolayers, and freshly isolated intestines from CF mice.
Materials and Methods
HTS assay
Screening was performed using BHK cells which stably express F508del-CFTR bearing three tandem haemagglutinin-epitope tags (3HA) and linker sequences in the fourth extracellular loop after amino acid 901 (Howard et al.,1995; Carlile et al., 2007) . Rescue of the mutant by test compounds was monitored in a plate reader as antibody binding after fixing the cells with paraformaldehyde (for details see Carlile et al., 2007) . All hits from the HTS assay are subsequently validated by immunoblot analysis for band C, and by measurement of cAMPstimulated iodide effluxes to determine the functionality of rescued CFTR. Finally, cells are treated with the hit compounds and CFTR localization is observed by immunofluorescence microscopy.
Compounds
42,000 diverse small molecules were tested in the initial screen (2,000 compounds from Microsource Discovery Inc, and 40,000 compounds from ChemBridge Corp). A total of 89 commercially available analogues of hit compounds from the screen were then identified in a computational search based on structural similarity and were tested under the same assay conditions.
Immunoblot analysis
Cell lysates were quantified using the Bradford assay (BioRad, Hercules, CA), separated by and analyzed by densitometry using the ImageJ program (National Institutes of Health).
Optical density of bands on the immunoblots was determined as follows: Maximal and minimal optical densities for the blot were measured and the values normalized (range 0-10 in Fig 2, and 0-12 in Fig 3) . The intensity of each band was then determined for each treatment and plotted against this scale to compare bands between treatments. Percent correction for any one treatment was determined from the proportion of signal in one band relative to the total signal for that treatment.
RNA extraction and quantitative real-time RT-PCR
We used a CFBE41o -airway epithelial cell line that was generously provided by Dr. J.P.
Clancy (Univ. Alabama at Birmingham) and cultured as described previously (Bebok et al., 2005) . The parental CFBE41o -cell line was originally developed from CF bronchial cells (F508del/F508del) by Dr. D. Gruenert and colleagues (Kunzelmann et al., 1993) , and later transduced with wild-type or F508del-CFTR using the TranzVector lentivirus system (Wu et al., 2000) . CFBE41o -cells were grown on 24 mm-transwell filters and exposed to 0.1% DMSO (untreated control) or 10 µM KM11060 (in DMSO) for 48 h at 37°C. Low temperature rescue of F508del-CFTR was carried out at 29°C for 48 h. RNA was extracted with Trizol (Invitrogen, USA) according to the manufacturer's instructions, except for an extra acid phenol:chloroform extraction to remove contaminating genomic DNA prior to adding alcohol, and the addition of 10 µg of Glycoblue (Ambion, Austin, TX) as a carrier.
All RNA samples were treated with DNase (Ambion, Austin, TX). under the following cycling conditions: 1 cycle at 95°C, 10 min; 45 cycles 95°C, 10 sec, 58°C 20 sec and 72°C for 10 sec followed by a melt curve.
Relative expression of CFTR was quantified using a standard curve that spanned 5 -6 logs, which was generated by serial dilution of cDNA from untreated CFBE41o -cells that had been reverse transcribed under the same conditions as the treated samples. Standard curves were included in every experiment for each gene analyzed. The efficiency was near 100% for all primer pairs used in this study.
Samples for each experiment were run in triplicate and experiments were repeated at least three times. 
Measurement of cytotoxicity
Toxicity of KM11060 was tested using the CellTiter-Glo assay from Promega, which monitors cell viability by detecting ATP levels as luciferin-luciferase bioluminescence (Crouch et al., 1993) . Briefly, KM11060 was dissolved in DMSO, diluted in cell culture medium to a final concentration of 1-300 µM (DMSO < 1%), and dispensed into 96-well microplates as 50-µl aliquots containing 15,000 BHK cells/well. After incubation at 37°C in a 5% CO 2 incubator for 24 h, cells were incubated for 1 h with reagents from the kit as recommended by the manufacturer. Luminescence was detected using an automated microplate reader (FLUOstar OPTIMA, BMG Labtech, Germany) and normalized to the control group that received only vehicle (DMSO). Cytotoxicity was calculated as the % decrease in luminescence relative to controls without drug. Three independent cytotoxicity assays were carried out at each drug concentration on different days.
Halide flux assay
Iodide effluxes were performed using a robotic liquid handling system (BioRobot 8000, 
Patch-clamp recordings
Whole-cell patch-clamp experiments were performed at room temperature (22°C-25°C) using This article has not been copyedited and formatted. The final version may differ from this version. , 10 mM mannitol (pH 7.4 with NaOH) + 100 µM amiloride to block any sodium absorption through epithelial sodium channels. The CaCl 2 concentration was increased to 4 mM to compensate for chelation of calcium by gluconate. The apical solution contained mannitol instead of glucose to eliminate current mediated by Na + -glucose cotransporters.
In the second set of experiments, apical membrane conductance was functionally isolated by permeabilizing the basolateral membrane with 200 µg/ml nystatin and imposing an apical-to- 
Ex-vivo experiments
Compounds were tested ex vivo using tissues from homozygous F508del/ F508del CFTR knockout mice (Cftr tm1 Eur
; van Doorninck et al., 1995) and wild-type littermates controls.
Mice were 14-17 weeks old, weighed 24-30 g, and were genotyped by standard PCR methods using tail DNA. The mice were kept in a pathogen-free environment in the animal facility at McGill University and fed a high protein diet constaining pork instead of beef (SRM-A, Hope Farms). All procedures followed Canadian Institutes of Health Research (CIHR) rules and were approved by the faculty Animal Care Committee. Ileal mucosa was stripped of muscle and incubated in William's E-Glutamax medium supplemented with insulin (10 µg/ml), 100 U/ml penicillin, and 100 µg/ml streptomycin and dexamethasone (1.6 ng/ml) containing 0.1% DMSO (control) or the appropriate concentration of KM11060 for 5 h. The tissue was rinsed repeatedly, then mounted in Ussing chambers to measure I sc .
Statistics
All results are expressed as the mean ± SEM of n observations. Sets of data were compared with either an analysis of variance (ANOVA) or Student's t-test. Differences were considered statistically significant when p<0.05. ns: non significant difference, * This article has not been copyedited and formatted. The final version may differ from this version. 
Results
Our HTS trafficking assay relies upon immunodetection of HA epitopes in the fourth extracellular loop of F508del-CFTR (for more details see Carlile et al., 2007) . A screen of 42,000 compounds with this assay yielded 25 strong hits; i.e., giving surface fluorescence ≥ three standard deviations above the mean for untreated cells, and many other compounds that were arbitrarily classified as medium (2 x s.d.) or weak hits (1 x s.d.). Intrinsic fluorescence of potential hit compounds was measured and the fluorescent compounds were excluded from further study. One of the hits was the phosphodiesterase inhibitor sildenafil, which was also observed in our previous screen (Carlile et al., 2007) and had been reported to be a CFTR corrector (Dormer et al., 2005) . In the present study, we used the HTS assay to test six structural analogues of sildenafil that carry the distinctive sulfonyl-piperazine group (Fig. 1) .
Five of these were also hits, with RJC03008 and KM11060 giving the strongest signals ( Fig.   2A ). Interestingly, KM11057 gave negligible correction whereas KM11060, which differs by only a single chlorine atom gave a strong positive signal. To further validate these hits, their effects were then analyzed by immunoblotting (Fig. 2B) . Correction of F508del-CFTR was confirmed by the appearance of band C for all analogues except KM11057, consistent with the results of the trafficking assay (Fig. 2B ). As shown in Fig. 2C , approximately 38% of the CFTR signal generated by cells following treatment with KM11060 was the band C glycoform. However the amount of band C was not strongly correlated with detection of 3HA
F508del-CFTR at the plasma membrane for all correctors. For example RJC03008 produced less band C than expected based on the screen, whereas JFD01738 produced more. These results suggest there may be variable sequestering of F508del-CFTR in post-Golgi compartments, or some of the protein detected on the cell surface may be a different (eg band B) glycoform.
This article has not been copyedited and formatted. The final version may differ from this version. Functionality of F508del-CFTR rescued by these compounds was examined using an automated iodide efflux assay (Fig. 2D , see Fig. 5A for representative time-course halide efflux curve). Treating cells with KM11060 (10 µM) for 24 h enhanced the cAMP-stimulated iodide efflux, indicating there was an increase in functional CFTR at the plasma membrane (Fig. 2D) . Under the same conditions, JFD01738 and the other positive hits did not increase efflux responses despite inducing the appearance of band C (Fig. 2D ). Since KM11060 gave the most band C and channel function in BHK cells, we investigated it in more detail.
To understand the dynamics of F508del-CFTR rescue by KM11060, we compared the time-course of correction and its concentration-dependence with those for sildenafil using the trafficking assay (Fig. 3A) . 10 µM KM11060 induced a 1.3-fold elevation of surface expression within 2 h, which increased to 1.75-fold increase after 24 h and then declined.
Significant correction was still detected after 96 h in the continued presence of drug. By contrast, 10 µM sildenafil did not correct noticeably until 6 h (1.5-fold increase), although it also peaked at 24 h and remained elevated after 96 h (Fig. 3A) . Fig. 3B shows that a KM11060 concentration of 10 nM was sufficient to elevate F508del-CFTR surface expression when cells were treated for 24 h. Trafficking increased with concentration and reached a maximum at 10 µM. Sildenafil was much less potent; requiring 1 µM to increase surface expression significantly, and 100 µM for a maximal effect (Fig. 3B) .
The time-and concentration-dependencies of KM11060 effects were analysed further by Western blotting, which confirmed the appearance of band C after 2 h when cells were treated with 10 nM (Fig. 3C) . Densitometry of Western blots from two independent experiments revealed that 25% of the F508del-CFTR was in the mature form (band C) after 2 h exposure (Fig. 3D) , and this increased to 50% after 24 h before declining to 43% after 72 h.
Importantly, 20% of the F508del-CFTR was detected as band C after 24 h when cells were exposed to only 10 nM KM11060, and this increased further to 50% at 1 µM before declining This article has not been copyedited and formatted. The final version may differ from this version. (Fig. 4A ). Relative expression of CFTR mRNA was 2 to 3.5-fold higher after low temperature (control, Fig. 4A ). KM11060 (10 µM) probably acts at the post-transcriptional level since it had no effect on the total expression of F508del-CFTR. We tested KM11060
for cytotoxicity at a range of concentrations (1 to 300 µM) using BHK cells. As shown in Fig.   4B , KM11060 was not cytotoxic up to 100 µM, although cell viability decreased ~25 % after 24 h at the highest concentration (300 µM).
F508del-CFTR is less responsive to cAMP stimulation (Hwang et al., 1997; Bebok et al., 2005) , therefore we examined whether F508del-CFTR channels rescued by KM11060 are active and determined the concentration at which functional correction is detectable. Similar results were obtained when iodide efflux assays were performed using BHK and human airway epithelial cells (CFBE41o -), therefore only those for CFBE41o -cells are shown in Fig.   5 . Treating CFBE41o -cells with 10 µM KM11060 for 24 h generated a significant iodide efflux response to 10 µM forskolin + 50 µM genistein whereas no response was observed in untreated CFBE41o -cells (Fig. 5A) . Different times and concentrations of KM11060 treatment were also tested and the results are shown in Figs. 5B and C. Iodide efflux from CFBE41o -cells was detected after 2 h treatment, reached a peak at 6 h, and then declined, although there was still detectable rescue after 96 h ( assayed for cAMP-stimulated iodide efflux at different time points up to 24 h (Fig. 5D ).
cAMP-stimulated iodide efflux was detected 6 h after removing KM11060 but had disappeared by 24 h (Fig. 5D) . In BHK cells, cAMP-stimulated iodide efflux remained relatively constant for 6 h after treatment, but also disappeared by 24 h (data not shown).
Iodide effluxes are convenient but provide only a qualitative assessment of CFTR activity since the driving force for iodide is unknown and declines with time. To examine functional rescue more rigorously, we measured the effect of KM11060 on whole-cell CFTR chloride currents in HEK293 cells stably transfected with F508del-CFTR. Recordings were compared before and after adding 10 µM forskolin + 30 µM genistein to control cells (0.1% DMSO) and to cells incubated at 29°C for 24 h and pre-treated with 10µM KM11060 for 48 h (Fig. 6A) . I-V relationships were normalized to cell capacitance ( Fig. 6B ) and the stimulated current density (pA/pF) at +80 mV is shown in Fig. 6C . Fig. 6D shows the rapid activation of F508del-CFTR in a cell treated with KM11060 and its sensitivity to the CFTR blocker glibenclamide measured at +80 mV (100 µM; Hwang and Sheppard, 1999) .
10 µM forskolin + 30 µM genistein stimulated only small whole cell F508del-CFTR currents when cells were treated with vehicle (0.1% DMSO) for 24 h (n = 3; Figs 6A, B and C). The mean current density at +80 mV was 24.84 ± 10.17 pA/pF, comparable to that measured before cAMP stimulation ( Fig. 6A ; DMSO). Incubating cells at 29°C for 24 h increased CFTR chloride current measured at +80 mV by 4-fold to 108.12.±.0.97 pA/pF, n = 2, Figs. A-C). The macroscopic I/V relationship was weakly outwardly rectifying ( Fig. 6B) , which is not uncommon for CFTR-mediated whole-cell current. The rectification may be due to flickery gating at negative potentials or incomplete cell dialysis with high-Cl -pipette solution, since outward rectification is much more pronounced in the cell attached configuration compared to excised patches (see Tabcharani et al., 1991) . Indeed, inward rectification of CFTR has been reported in excised patches, and was ascribed to voltageThis article has not been copyedited and formatted. The final version may differ from this version. (Cai et al., 2003) .
The same agonists stimulated much larger F508del-CFTR-mediated currents (167.42 ± 29.77 pA/pF (n = 5) at +80mV) when cells were incubated with 10 µM KM11060 at 37°C for 48 h.
Taken together, the activation by forskolin + genistein, linear current-voltage relationship, and sensitivity to glibenclamide provide strong evidence that the whole cell currents and iodide effluxes are mediated by F508del-CFTR, and indicate that KM11060 increases cAMPstimulated channel activity by ~6-fold in this cell type.
To test the corrector activity of KM11060 using a more physiologically relevant cell type, we studied monolayers of the CF airway epithelial cell line CFBE41o
-(F508del/F508del) cultured on permeable supports (Bebok et al., 2005) . To monitor CFTRdependent I sc , a basolateral-to-apical Cl -gradient was imposed for 15-30 min and 100 µM amiloride was added to the apical side to block apical Na + conductance. respectively. Forskolin and genistein had no effect on the untreated cells kept at 37 o C ( Fig.   7A ) but did stimulate current across monolayers that had been incubated at low-temperature, and these were sensitive to the CFTR channel blocker CFTR inh -172 (10 µM; Ma et al., 2002) .
KM11060 treatment (20 µM for 48 h) increased the forskolin + genistein-stimulated I sc by about 37-fold compared with DMSO controls (Fig. 7C, D) . The compound-corrected I sc was blocked by CFTR inh -172, suggesting that the entire stimulation was mediated by rescued F508del-CFTR (Fig. 7C ). Correction by KM11060 was 26% (n = 6) of that induced by lowtemperature (n = 5, Fig. 7D ), which was significant but less than noted above for HEK 293 cells in patch clamp experiments. The basolateral membrane was permeabilized using nystatin in some experiments to confirm that the stimulated I sc was mediated by apical Cl of the current relative to low-temperature incubation (Fig. 7E ), similar to that seen using unpermeabilized monolayers.
Finally, we measured the effect of KM11060 treatment on intestinal tissue isolated from CF mice that were homozygous for F508del-CFTR. The I sc response to forskolin and its sensitivity to CFTR inh -172 were examined after ex-vivo exposure to 20 µM KM11060 for 5 h. 
Discussion
Defective F508del-CFTR folding and trafficking can be overcome by small molecules (Loo et al., 2005; Van Goor et al., 2006; Wang et al., 2007) , however the correctors identified to date have relatively low potency. In this screen of 42,000 chemically diverse molecules we obtained several distinct groups of "hit" compounds. One of these was the PDE5 inhibitor sildenafil, which has been reported previously to correct F508del-CFTR trafficking (Dormer et al., 2005; Carlile et al., 2007 provide therapeutic benefit for CF patient (Johnson et al., 1992; Farmen et al., 2005) . Thus KM11060, which is effective at 10 nM, and other analogues of sildenafil are suitable starting points for further optimization of potency, efficacy, and selectivity, and should be evaluated for their pharmacokinetic and toxicological properties.
Sildenafil is a potent inhibitor of cGMP-specific phosphodiesterase 5 (PDE5) and is marketed as a treatment for erectile dysfunction (Viagra
. A previous study demonstrated improved CFTR processing and conductance in nasal cells from CF patients after they were treated with 150 µM sildenafil (Dormer et al., 2005) , and sildenafil also hit in a recent HTS screen for CFTR correctors (Carlile et al., 2007) . In the present study we identified a structural analogue of sildenafil which is much more potent and is also efficacious in native tissue. The cellular mechanism remains to be elucidated, however the results imply a role for PDEs and cGMP in CFTR processing. Interestingly, increasing cGMP levels in CF respiratory epithelial cells may correct several aspects of CF pathology including abnormalities in protein glycosylation, bacterial adherence and proinflammatory responses (Poschet et al., 2007) . Consistent with that report, we found in preliminary experiments that KM11060 inhibits PDE5 activity and transiently increases cGMP levels (data not shown).
Such increases in cGMP level could transiently increase cGMP-dependent protein kinase D.
